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ABSTRACT 
The extracellular matrix (ECM) of articular cartilage is comprised of complex networks of proteins 
and glycoproteins, all of which are expressed by its resident cell, the chondrocyte. Cartilage is a 
unique tissue given its complexity and ability to resist repeated load and deformation. The 
mechanisms by which articular cartilage maintains its integrity throughout our lifetime is not fully 
understood, however there are numerous regulatory pathways known to govern ECM turnover in 
response to mechanical stimuli. To further our understanding of this field, we envision that proteomic 
analysis of the secretome will provide information on how the chondrocyte remodels the surrounding 
ECM in response to load, in addition to providing information on the metabolic state of the cell.  In 
this review, we attempt to summarize the recent mass spectrometry-based proteomic discoveries in 
healthy and diseased cartilage and chondrocytes, to facilitate the discovery of novel biomarkers linked 
to degenerative pathologies, such as osteoarthritis (OA). 
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INTRODUCTION 
To gain a deeper understanding of the mechanisms that drive osteoarthritis (OA), it is 
important to appreciate the underlying biology of healthy and diseased joint tissues. Of interest is the 
pathophysiology of articular cartilage, and the processes that govern synthesis and organisation of 
extracellular matrix (ECM) components secreted by chondrocytes into the pericellular milieu. The 
chondrocyte is the unique resident cell of articular cartilage and thus solely responsible for ECM 
composition and regulation. Chondrocyte metabolism is influenced by its micro-environment, and in 
return influences ECM composition, organization and ultimately the mechanical resilience of cartilage 
[1-3]. As such, chondrocytes play a key role in ECM remodelling in physiological and pathological 
conditions [4]. 
 
It is commonly established that healthy articular chondrocytes change into different phenotypes as OA 
develops and progresses: 
(i) A catabolic phenotype develops, associated with an increase in proteolytic enzymes and 
reactive oxygen/nitrogen species, in response to mechanical stress and inflammatory 
cytokines, tumour necrosis factor (TNF)-and interleukin (IL)-1, leading to further ECM 
degradation. 
(ii) An anabolic phenotype emerges that is associated with regeneration of the ECM, including 
increased collagen type II and proteoglycan expression regulated by growth factors 
(transforming growth factor (TGF)-, bone morphogenetic protein (BMP)s and insulin 
growth factor (IGF)-I), expressed either by the surrounding joint tissue or by the 
chondrocytes themselves. 
(iii) A hypertrophic phenotype develops, manifesting in expression of type X collagen and 
induction of apoptosis, ultimately resulting in osteophyte formation. 
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(iv) A fibroblastic-like phenotype with an increased number of dedifferentiated chondrocyte and 
expression of type I collagen. 
(v) Lastly, a chondroblastic phenotype emerges with expression of foetal type IIA collagen, type 
III collagen and early/late differentiation markers[5]. 
 
The specific phenotype that any individual chondrocyte exhibits is dependent on the zone in which the 
chondrocyte is situated and the stage of OA progression. In the upper zone, cellular proliferation and 
hypertrophy are observed, whereas the mid and deep zones display increased expression of type II 
collagen [6]. As OA progresses, cartilage is lost and chondrocytes undergo senescence, due to a 
combination of replicative exhaustion and oxidative stress [7].  
Eventually, chondrocytes will undergo apoptosis, and the articular cartilage will be destroyed. The 
ultimate goal of mass spectrometry-based proteomics strategies is the identification of a specific 
tissue-derived secretome that is unique to the diseased chondrocyte and surrounding ECM and is able 
to distinguish between healthy and diseased cartilage. 
Because protein expression is dependent on environmental conditions, the secretome is highly 
dynamic in composition and turnover. In 2010, Agrawal et al. suggested defining the secretome as 
“the global group of secreted proteins into the extracellular space by a cell, tissue, organ, or organism 
at any given time and conditions through known and unknown secretory mechanisms involving 
constitutive and regulated secretory organelles”[8]. In this narrative review, we only considered the 
chondrocyte (or cartilage) as the source of secreted proteins, which have been uncovered by state-of-
the-art mass spectrometry-based proteomics techniques. 
Proteomic techniques include different methods, all relying on the separation of proteins and their 
further analysis using either gel-based (Two-dimensional electrophoresis) or gel-free methods. Protein 
separation methods are coupled to a mass spectrometer for identification of sequence by mass 
spectrometry [9, 10]. In differential analysis, the peptides may be marked with stable isotope at various 
stages of the analysis process, or Label-free methods could be performed. Several modes of analysis are 
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available in mass spectrometry[10]. They differ markedly by the ionization source of the sample. The 
main sources used in proteomic analysis are matrix-assisted laser desorption/ionization (MALDI) and 
surface-enhancer laser desorption/ionization (SELDI) [10, 11]. These techniques allow a soft ionization 
of molecules without excessive fragmentation [9, 11]. 
More than the total tissue protein extract, it is expected that well-defined protein fractions such as the 
secretome could be a source of novel OA biomarkers, with the potential to predict disease severity and 
monitor progression. 
 
MATERIALS AND METHODS  
A literature search was performed in Pubmed/Medline and Scopus, identifying articles published 
between January 2004 and March 2016. Keywords used in 'Any fields' were;  (chondrocyte OR 
cartilage) AND secretome (19 relevant papers out of 38 found), or (chondrocyte OR cartilage) AND 
(proteomic OR mass spectrometry) (65 articles relevant papers out of 290 found). Only results from 
mass spectrometry-based studies were included in this article. The review has considered all species, 
even if  the majority of  studies have been performed on human source of chondrocytes or cartilage. 
Only research articles published in English were included. Supplementary files of all papers were 
analysed and included in this review. 
CHONDROCYTE SECRETOME 
Recent mass spectrometry-based proteomic studies have identified several proteins which form the 
chondrocyte secretome. In this part of the review, we focused on proteins identified either directly in 
the secretome of cartilage explants [12-20] or chondrocytes cultures [18, 21-31]), both of which are 
listed in Table 1. We further complete this list with proteins recently identified by proteomic analysis 
performed directly on fresh chondrocytes or cartilage tissue[32-36] (sometimes de-cellularized [37]) 
whereby different locations in the joint were compared, or healthy joint tissues were compared with 
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OA tissues. The characteristics of all these studies are summarized in Table 2. Proteins have been 
classified in different sections: ECM proteins, cytokines and growth factors, enzymes and 
miscellaneous. 
ECM proteins 
As expected, the most abundant ECM proteins produced by chondrocytes, and detected by proteomic 
analysis, are collagens and proteoglycans, Table 1. 13 collagens are found in the chondrocytes 
secretome, of which type II, VI and XII are the most abundant[35]. Collagen type XII is also known to 
interact with other cartilage elements such as cartilage oligomeric matrix protein (COMP), decorin and 
fibromodulin [38].  Collagen type II and VI levels are increased in the secretome of chondrocytes 
taken from the medial condyle of patients with early OA (Mankin score 0-3), compared with samples 
taken from patients with severe OA (Mankin score 5-10) [25]. 
Beside the collagens, other ECM proteins found in high abundance in the chondrocyte secretome 
include; aggrecan, HPLN-1 (proteoglycan link protein), biglycan, COMP, fibronectin, prolargin 
(Proline-arginine-rich end leucine-rich repeat protein (PRELP)), matrilin-3, cartilage acidic protein-1 
(CRTAC1 or ASPIC), latent-transforming growth factor beta-binding protein-1 (LTBP1), extracellular 
matrix protein-1 (ECM-1), tenascin, lubricin and chitinase-3-like protein 1 (CHI3L1), also known as 
YKL-40). CHI3L1 was found at lower levels in cartilage explants treated with IL-1β compared to 
controls[12]. CHI3L1, is a biomarker of OA found in synovial fluid and serum[39], and plays a role in 
tissue remodelling and inflammation. The concentration of CHI3L1 in OA synovial fluid positively 
correlates with levels of matrix metalloproteinase (MMP)-1, MMP-3, IL-6 and IL-17. 
IL-6 and IL-17 enhanced CHI3L1 production in human primary chondrocyte cultures[40] and CHI3L1 
serum concentration positively correlated with osteophyte size in OA patients[41]. This protein is 
more abundant in knee compared to hip cartilage [37] and in OA compared to healthy cartilage [27] 
and is considered to be an early OA biomarker in the Stenberg’ proteomic study, which compared 
early and severe OA secretomes [25]. 
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In comparison with normal cartilage explants, CRTAC1 is found elevated in the OA cartilage 
secretome [13]. This protein is considered a cartilage specific protein, appearing early during 
chondrocyte differentiation of mesenchymal stem cells (MSCs) [26]. Expression of CRTAC1 allows 
discrimination between human chondrocytes and osteoblasts, or MSCs, in monolayer cell culture [26, 
42]. This protein is therefore considered a good marker of chondrocytic differentiation of MSCs. 
LTBP1 also seems to be an important ECM protein secreted early in the differentiation of MSCs to 
chondrocytes [26]. Beside its structural role in the ECM, this protein is involved in the storage and the 
activation of TGF-β1, and therefore may play an important role in facilitating cartilage homeostasis. 
ECM-1 is a protein involved in endochondral bone formation serving as a negative regulator of bone 
mineralization [43]. It is able to enhance the proliferation of endothelial cells during angiogenesis[44] 
and inhibit MMP-9 proteolytic activity[45]. Louridos et al observed that the level of ECM-1 secreted 
by cells originating from damaged OA cartilage is 3-fold higher than that of healthy cartilage [13]. 
Periostin secretion from explants increases with cartilage degradation [13], and was only found in 
cultured OA chondrocytes [35]. Expression of periostin was previously shown to be elevated in OA 
cartilage compared to normal, and located in the pericellular ECM close to damaged areas of cartilage 
[46, 47]. Periostin is able to increase expression of IL-6, IL-8, MMP-1,-3,-13 and a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS)-4 by chondrocytes in vitro[46, 47]. 
Fibronectin and fibromodulin are secreted at comparable levels by OA and normal chondrocytes, but 
fragmentation of these ECM proteins is found to differ depending on whether the cell is healthy or 
diseased [36, 48]. 
Cytokines and growth factors 
Classical cytokines and chemokines like IL-6, IL-8, CCL8-20, CXCL1-3-5-8, CSF-1 are detected by 
tandem mass spectrometry only after an IL-1β stimulation of chondrocytes, cultured either in explant 
or in monolayer [12, 14, 19, 22, 27]. 
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The IGFBP family is widely represented in chondrocyte secretome by IGFBP-2,-3,-4,-5,-6 and -7 [12, 
21, 22, 24-27]. Expression of IGFBP-3,-4,-6 and -7 is increased in early OA [25]. These proteins serve 
as a carrier protein for IGF-1 and modulate the availability of IGF-1 to bind its receptor. Furthermore, 
IGFBP3 is known to induce chondrocyte apoptosis during OA[49]. In contrast IGFBP5 that has a 
positive role in cartilage anabolism, and inhibits enzymatic degradation; in fact IGFBP3 promotes 
cartilage extracellular matrix formation  in vivo in the DMM OA rat model [50]. 
Among growth factors detected in the chondrocyte secretome, gremlin-1, chondromodulin and 
pleiotrophin are known to be involved in hypertrophic differentiation regulation. Gremlin-1 is a BMP 
antagonist presenting reduced secretion from OA chondrocytes compared to normal [14][35], and 
plays an important role in bone development by inhibiting bone formation [51]. Gremlin-1 is 
therefore, potentially, a potent inhibitor of chondrocyte hypertrophy in cartilage. Chondromodulin is 
also important for chondrocytes stabilization, acting by inhibiting hypertrophic differentiation, and is 
shown to be secreted only by superficially located chondrocytes [34]. Pleiotrophin is a secreted 
heparin-binding peptide expressed in mesodermal and neuroectodermal cells during development, but 
rarely in adult tissues. Pleiotrophin is abundant in foetal and juvenile cartilage, but not in mature. 
Furthermore, pleiotrophin is re-expressed in chondrocytes in early OA, and is involved in the 
clustering and proliferation of chondrocytes observed in the early stages of OA [52]. Pleiotrophin is an 
inducer of hypertrophy during chondrogenic differentiation of MSCs [53] and is also a potent pro-
angiogenesis factor. 
Proteolytic enzymes and their regulators 
Proteomic analysis of the chondrocyte secretome shows that the most abundant family of enzymes 
secreted is the MMPs, along with their endogenous inhibitors, the TIMPs.  MMP-1 and 3, and TIMP-
1, are particularly abundant. TIMP-3 appears to be more abundant in normal hip cartilage than knee, 
but MMP-1 is contrarily abundant in normal knee cartilage [37]. According to these studies,  MMP-13 
was only identified  following IL-1β-stimulation [15], or is at very low levels without stimulation [14]. 
With the exception of MMP-2 [13], MMP protein levels do not vary substantially between normal and 
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OA chondrocytes, but all increase with IL-1β treatment. TIMP-1 and -2 levels are decreased in OA 
medial condyles [25], and TIMP-1 is increased with TGF-β1 stimulation [24]. 
The other family of metalloproteinases expected to be found in cartilage is the ADAMTSs. Although 
ADAMTSs were found in some proteomic secretome studies [12, 22, 25], they were not identified in 
all studies; most likely due to varying extraction methods which can eliminate ADAMTSs, along with 
the glycosaminoglycan (GAG) attachments of proteoglycans [15]. ADAMTS's may not be easily 
identified in mass spectrometry-based proteomic studies also due their relatively low abundance. 
Indeed, saturation of detectors with high abundance ions, type of protease used in mass spectrometry 
based studies (mainly trypsin) which may lead to non-identification of ionized peptides as they are too 
small, too large or contain amino acid sequences less likely to be 'seen' following ion identification. 
Positive studies, which identified ADAMTSs in the secretome, were all performed using OA 
chondrocytes or OA cartilage explant culture [12, 22, 25]. A recent study published by Svala, showed  
that  peptides cleaved from aggrecan, following IL-1β stimulation in chondrocytes, were generated by  
MMPs, but not by ADAMTSs [14]. This finding confirms the importance of MMPs in cartilage ECM 
breakdown mediated by IL-1β. However, the fragmentation patterns, and differential distribution 
between cartilage and synovial fluid, are consistent with the existence of at least two proteolytic 
pathways for aggrecan degradation in human OA, generating both 342FFGV- and 374ARGS-fragments 
[54]. Both the MMP-generated N-terminus of 342FFGV- fragment and the aggrecanase 374ARGS- 
fragment are found in the OA synovial fluid, but only the 342FFGV is found in cartilage tissue itself 
[54].  
A further intriguing proteomic study was conducted to elucidate the target of MMPs and ADAMTSs 
in articular cartilage [20, 55]. Human articular cartilage[55] or crude equine cartilage proteoglycan 
extract[20] was digested by the addition of exogenous metalloproteases, including MMP-2, -3, -8, -9, -
12, and -13 and the aggrecanases ADAMTS-4 and ADAMTS-5. Digestion products were identified by 
proteomic methods, and complete sequences of generated peptides were determined. A wide variety of 
peptides, originating from collagen types I, II, and III, biglycan, prolargin, fibromodulin, fibronectin, 
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decorin, COMP, cartilage intermediate-layer protein, megakaryocyte-stimulating factor, clusterin, 
mimecan, aggrecan, and lumican, were obtained [20, 55]. MMP-2 was the most active protease used in 
the study, and the aggrecanases were the least active in generating peptides from cartilage digestion. 
The aggrecanases showed a preference for cleaving proteoglycan-containing proteins. However, all of 
the proteases cleaved many types of cartilage ECM proteins [55]. Interestingly, IL-1β treatment 
generated many COMP neopeptides [14, 20]. Some biglycan and COMP neopeptides were identified 
as being generated by ADAMTS-4 or MMP-3 and even increased by IL-1β concerning COMP [20] 
are found increased in the horse OA synovial fluid compared to normal one, i.e. 191CIEMGGNPL for 
biglycan and 149CEACPPGYSGPTHEGVGM166 and 87AQCAPGSCFPGVACTQ102 for COMP[56]. 
Proteomics studies also highlight a serine protease, HTRA1, as one of the most abundant secreted 
protein by chondrocytes. This enzyme cleaves aggrecan, within the interglobular domain, in human 
cartilage [57]. Levels of HTRA1-generated aggrecan fragments, containing the VQTV(356) 
neoepitope, were significantly elevated in OA cartilage compared with cartilage from healthy joints; 
implicating HTRA1 as a critical protease involved in proteoglycan turnover and cartilage degradation 
during degenerative joint disease [57]. Cleavage of aggrecan by HTRA1 was strongly enhanced by 
HTRA1 agonists such as CPII, a C-terminal hexapeptide derived from the C-propeptide of procollagen 
IIα1 [57]. HTRA1 is preferentially localized in the deep layer of cartilage [34] and increased during 
chondrocyte differentiation of MSCs [26], and by TGF-β1 stimulation [24]. HTRA1 is reduced 4-fold 
in OA vs normal chondrocytes [35], with no difference detected between OA and normal 
decellularized cartilage [37]. 
Procollagen C-endopeptidase enhancer (PCOLCE)-1, and 2, are proteins which enhance procollagen 
C-proteinase activity, commonly identified in many proteomic studies. Furthermore, the C-terminal 
processed domain of PCPE (CT-PCPE) may have metalloproteinase inhibitory activity. PCOLCE1 is 
increased during chondrocyte differentiation of MSCs [26] and in OA cartilage [37], but is decreased 
with IL-1β [14, 15] and with TGF-β1 [24]. 
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Other enzymes that could be important in the regulation of collagen metabolism are the procollagen-
lysine,2-oxoglutarate 5-dioxygenases 1 and 2. Expression of these enzymes is increased upon IL-1β 
stimulation [22, 58], and they could be responsible for an over glycosylation of collagen fibrils, 
observed in OA, which decreases fibril flexibility [58]. 
Another set of enzymes found to be greatly increased in the OA chondrocyte secretome are the 
lysosomal enzymes, including cathepsins, phospholipases, peroxiredoxins, ovochymase-1 [36, 37].  In 
fact, cathepsin activity based probes have detected increased cathepsin B activity in blood and 
synovial fluid of early OA patients, while cathepsin S was associated with RA [59]. 
Other enzyme families detected in chondrocyte secretome comprise of SERPINs, superoxide 
dismutases (SODs), triosephosphate isomerase and lysozyme C enzymes. These are modulated by IL-
1β, but are not significantly modified with the disease, except SERPINA3. SERPINA3, also known as 
α1-antichymotrypsin, is mainly located in the superficial layer of the articular cartilage [34] and is 
decreased during OA [35]. 
Miscellaneous Secretome Proteins 
The chondrocyte secretome contains many proteins involved in cellular regulatory pathways, cell-cell 
or cell-ECM interactions, including chaperons, alarmins, apolipoproteins and chondrocalcin. 
Chondrocalcin is the C-terminal of type II collagen, associated with the calcification of cartilage ECM. 
Gelsolin, clusterin and transforming growth factor-beta-induced protein ig-h3 (TGF appeared in 
nearly all secretome studies and are one of the most highly secreted proteins by chondrocytes [14-19, 
22, 24, 26, 30, 34, 35, 37]. Gelsolin is increased in OA compared to normal chondrocytes[35, 37]. 
Clusterin inhibits protein aggregation and apoptosis. This protein is detected more in healthy than 
osteoarthritic cartilage[37]. TGFBI is known to be involved in the interaction of the cell with type II 
collagen, and plays an important role in endochondral bone formation. Indeed, this factor is an 
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inhibitor of mineralization. It was found to be highly secreted by OA chondrocytes, compared to 
normal chondrocytes[13], and present at a greater abundance in hip OA than healthy cartilage[33]. 
Osteonectin is involved in ECM-cytokine interactions. Similar to osteopontin, osteonectin is highly 
secreted in deep layer chondrocytes[34], and found to be increased in the secretome of medial 
condylar early OA cartilage[16, 25, 27]. TGF-β1 decreases the production of osteonectin[24]. 
Finally, thrombospondin-1,-3,-4 are all involved in cell-ECM interaction and angiogenesis, and are 
also secreted by chondrocytes [13, 14, 17, 19, 21, 24, 32, 34, 35, 37]. They are more abundant in the 
superficial layer of cartilage[34]. Thrombospondin-3 is increased in OA compared to normal 
chondrocyte secretomes[13], and thrombospondin-1 is increased with IL-1β treatment[19]. 
DISCUSSION 
The “omics” approach is a general exploratory approach used to investigate alterations in an 
enormous number of genes, transcripts, proteins, lipids and metabolites, in healthy versus 
diseased tissues. The challenge of using this approach is to identify those candidates that are 
specifically involved in the disease process. The most commonly used omics approaches 
include genomics, proteomics, lipidomics, metabolomics and transcriptomics. Such “omics” 
technologies applied to serum or urine samples have uncovered numerous new biomarkers, 
which are ubiquitous molecules in most cases. Therefore, it would be beneficial to refine 
“omics” technologies specifically to joint tissues (cartilage, bone, meniscus, synovial 
membrane) and compare “omics” profiles of the various articular tissues taken at different 
stages of evolution and correlate those amongst the various diseased tissues for the joint. In 
particular, the secretome of chondrocytes is of great interest because this approach provides a 
range of biomarkers reflecting the metabolic changes occurring in the main tissue affected by 
OA. Further, by investigating the chondrocyte secretome we increase the chance of 
identifying a circulating biomarker specific to disease, even specific to a particular joint. In 
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this paper, we have reviewed and summarized data produced by proteomic analysis of 
cartilage or chondrocyte culture supernatants. Interestingly, some proteins have been found to 
increase in the secretome of OA explants or OA chondrocytes, while few were found 
decreased in comparison with normal secretome. Among these, some have been found in 
synovial fluid, serum or urine and proposed as potential biomarkers. For example, type II 
collagen[60-64], aggrecan[63, 65, 66], lumican[67, 68], COMP[64, 66], gelsolin[67, 69], 
fibulin-3[70], mimecan[69], periostin[13, 71, 72], SERPINs[67, 70, 73] are found in these 
fluids in their native form, but also post-transcriptionally modified and/or fragmented. Some 
of these proteins or protein fragments have demonstrated to be burden of disease, prognostic, 
and efficacy of intervention or diagnostic soluble biomarkers, according the Burden of 
Disease, Investigative, Prognostic, Efficacy of Intervention and Diagnostic (BIPEDS) criteria. 
Some peptides generated during type II collagen degradation have been particularly well 
investigated, because type II collagen is the most specific protein of cartilage. Further, their 
concentration appears to be modified in joint disease. As previously mentioned, many 
aggrecan neoepitopes are found in cartilage tissue, but those generated by aggrecanases are 
largely released from cartilage and found in blood circulation, while  the majority of 
fragments generated by MMPs remain entrapped  in the tissue[54]. 
Although the proteomic approach is a good approach to study secretome, there are some 
limitations associated with this method. Quantitative assessment of proteins secretome using 
these proteomic techniques remain hazardous, because the method promotes the 
quantification of some proteins relative to their solubility, binding to other components, their 
size, length, amino acid sequence and also their post-translational modifications. Small 
proteins, like cytokines, give few peptides after tryspinisation, and because at least 2 peptides 
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are needed to assure the identification of the protein, they are probably excluded from the 
final observation. 
In addition, there are some missing links in the secretome study. For example, there is to date 
few studies really dedicated and designed to investigate the dynamic kinetics of cartilage 
metabolism during OA disease. Most of the studies compare healthy and end-stage OA 
chondrocyte secretome, with the aim to discover new proteins secreted by the chondrocytes. 
For example, CRTAC1, HTRA1, PCOLCE, LTBP1, ECM-1, gremlin-1, clusterin, have been 
identified using this approach and now need more investigations to decipher their role in 
chondrocyte metabolism during OA pathogenesis. 
The abundance of diverse models used in these proteomics studies also make them difficult to 
interpret. In monolayer, chondrocytes certainly have a different secretome than in their native 
3D environment[31]. In explant culture, the majority of the newly synthesized proteins 
remains entrapped in the ECM and only degraded products are released into the 
supernatant[18]. Mechanical stimulation of the explant should be performed to mimic the 
physiological flow and help the protein to be released from tissue. 
Posttranslational modifications like glycosylation, glycation, nitration are seldom 
investigated. A metabolomics approach would allow to investigate these changes and to 
complete knowledge coming from proteomic. 
Many supposed cytoplasmic proteins are found in the chondrocyte secretome using proteomic 
technics. This finding seems surprising but can be explained by the secretion of ECM-derived 
vesicles by chondrocytes. Articular cartilage vesicles (ACVs) are 50–150 nm membrane-
bound extracellular organelles found in normal articular cartilage. They were initially 
characterized in reference to their role in pathologic mineralization in cartilage in studies 
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which mirrored those of matrix vesicles derived from growth plate cartilage and other 
normally mineralizing tissues. ACVs contain enzymes, ions and substrates necessary for 
mineral formation[74]. The presence of these ACVs explain why cytoplasmic/membrane 
proteins, such as annexins, have been identified in the secretome of the chondrocytes. 
Transmembrane proteins can also be cleaved leading to the release in the extracellular space 
of extracellular part of the protein, which is the case of syndecans [75]. Another explanation 
at the presence of membrane proteins in the secretome is the presence of apoptotic cells, 
mainly during OA[76-78]. Loss of cell integrity during apoptosis further contribute to emerging 
proteins and pathway end-products in synovium and other bodily fluids, potentially giving 
rise to several biomarkers which may predict the susceptibility of an individual to develop 
OA. 
Pro-inflammatory cytokines, prostaglandins and reactive oxygen species (ROS) activate the normally 
quiescent articular chondrocytes and induce them to undergo a phenotypic shift through a 
phenomenon recently described as “chondrosenescence”, leading to further disruption of homeostasis 
and metabolism in cartilage [7]. Effectively, chondrosenescence is the term that describes the age-
dependent deterioration of chondrocyte function and how it undermines cartilage function in OA. 
Until now, this particular phenotype has not yet been investigated by proteomic technics. This should 
be added in the research agenda.  
 
In conclusion, proteomic analysis of chondrocytes secretome is a promising approach for 
detecting changes in chondrocyte metabolism linked to OA diseases (Table 1). This review 
listed the advantages and disavantages of secretome investigation using the proteomic 
methods.  The main limitations is the lack of standardization of the culture protocols, while 
the main advantage is the possibility to compare different environmental condition on the 
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secretome. We have also suggested some research perspectives, including comparison of 
secretome at different disease stages. Definitively, research on secretome using proteomic 
methods have to be encouraged with the objectives to identify new biomarkers reflecting 
chondrocyte metabolic changes in OA.  
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FIGURE LEGEND 
Figure 1 
Schematic representation of the chondrocyte secretome, based on data from mass-
spectrometry based proteomic studies. 
ADAMTS: A Disintegrin And Metalloproteinase with Thrombospondin Motifs, Apo: 
apolipoprotein, BMP: Bone morphogenetic protein, CCL: Chemokine ligand, CHAD: 
Chondroadherin, ChM: chondromodulin, CILP: Cartilage intermediate layer protein, CHI3L1: 
Chitinase-3-like protein 1, COMP : Cartilage oligomeric matrix protein, CRLF: Cytokine 
receptor-like factor, CRTAC: Cartilage acidic protein, CSF: Macrophage colony-stimulating 
factor, CTGF: Connective tissue growth factor, Cx: connexin , CXCL: C-X-C motif 
chemokine ligand,  ECM: extracellular matrix protein, ENPP: Ectonucleotide 
pyrophosphatase/phosphodiesterase family member, EMI: emilin,  HSPA5: 78 kDa glucose-
regulated protein, HTRA:  High-temperature requirement A serine peptidase, IL: Interleukin, 
LTBP: Latent-transforming growth factor beta-binding protein, MGP: matrix gla protein, 
MMP: matrix metalloproteinase, PCOLCE: Procollagen C-endopeptidase enhancer, PLOD:  
Procollagen-lysine,2-oxoglutarate 5-dioxygenase, PRELP: proline-arginine-rich end leucine-
rich repeat protein, SERPIN: serine protease inhibitors, SOD: superoxide dismutase, SPARC: 
Secreted protein acidic and rich in cysteine, TGFBI: Transforming growth factor-beta-induced 
protein ig-h3, TGF: transforming growth factor, TIMP: tissue inhibitor of metalloproteinase, 
TNAP: tissue non-specific alkaline phosphatase, TSP: thrombospondin. 
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TABLES 
 
Table 1 
Table 1: Summary of recent mass spectrometry-based proteomic studies carried out on human 
chondrocytes and cartilage to identify secretome components.  
ECM Proteins Specificity OA vs 
normal 
with IL-1β References 
Aggrecan core protein  ↘  [13, 14, 17, 18, 
20, 22, 27, 31-
37] 
Asporin    [32, 34, 37] 
Basement membrane-specific 
heparin sulfate proteoglycan core 
protein (PGBM) 
 ↗  [13, 18, 20, 30] 
Biglycan  ↗  [13, 14, 17, 18, 
20-22, 27, 30, 
32-37] 
Cartilage acidic protein-1 
(CRTAC1, ASPIC) 
Specific 
chondrocyte 
marker 
↗  [13, 16, 22, 26, 
33, 35] 
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Chitinase-3-like protein -1, -2 Tissue 
remodelling, 
inflammation 
↗ ↘ [13, 16, 18, 20-
22, 24, 25, 27, 
30, 31, 33, 35, 
37] 
Chondroitin sulfate proteoglycan 
4 (CSPG4) 
   [18] 
Collagens type I, II, III, V, VI, 
VIII, IX, X, XI, XII, XIV, XV, 
XVI 
 ↗  [13, 14, 16, 18, 
20, 21, 24-27, 
30-35, 37] 
Cartilage oligomeric matrix 
protein (COMP) 
 ↗  [13, 14, 17, 18, 
20, 22, 26, 27, 
30-35, 37] 
Decorin    [12-14, 18-21, 
27, 30, 32, 34, 
35, 37] 
Extracellular matrix protein-1 negative regulator 
of bone 
mineralization, 
promote 
angiogenesis, 
inhibit MMP-9 
activity 
↗  [13, 14, 19, 22, 
25, 33] 
Fibrillin-1    [18, 22, 25, 27, 
30, 35, 37] 
22 
 
Fibromodulin   ↗ [14, 16-20, 22, 
24, 26, 27, 32-
34, 36] 
Fibronectin    [14, 16-18, 20-
22, 26, 27, 30, 
32, 34, 35, 37] 
Fibulin-1, -3, -4, -7  ↗  [13, 18, 20-22, 
24, 25, 27, 30, 
33, 34] 
HPLN-1 (proteoglycan link 
protrein-1) 
Bind hyaluronic 
acid and aggrecan 
↗ ↗ [13, 14, 18, 19, 
22, 24, 27, 32-
35, 37] 
Latent-transforming growth factor 
beta-binding protein -1, -2 
(LTBP1, 2) 
Storage/activation 
TGF-β1, 
structural role in 
ECM 
  [13, 20, 26, 27, 
30] 
Lubricin (proteoglycan-4)  ↗  [13, 14, 18, 20-
22, 26, 27, 30, 
32-35, 37] 
Lumican    [13, 14, 16, 18-
22, 24, 25, 27, 
30, 32-35, 37] 
Matrilin-2*, -3*    [25, 33-35, 37] 
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Matrix gla protein (MGP)  ↗ ↗ [14, 19, 20, 22, 
24, 26, 33-35, 
37] 
Mimecan (osteoglycin)  ↗  [13, 18, 22, 27, 
30, 32-34, 37] 
Osteomodulin    [18, 22, 30-32, 
34, 37] 
Periostin  ↗  [13, 22, 35] 
Perlecan    [34, 37] 
Prolargin (PRELP) Bind type II 
collagen and 
perlecan 
  [13, 17, 18, 20, 
22, 25, 27, 32-
37] 
Syndecan-2, -4   ↗ [19, 21, 35] 
Tenascin C, X  ↗  [13, 18, 20-22, 
30-32, 34, 35, 
37] 
Versican  ↗  [13, 32, 34, 37] 
Cytokines and Growth Factors Specificity   References 
CCL2, -8, -14, -20   ↗ [14, 21, 22, 25, 
33] 
24 
 
CSF-1   ↗ [21, 27] 
CTGF    [16, 18, 20, 22, 
24, 30, 31, 33] 
CXCL1, -3, -5, -6   ↗ [27, 33] 
Cytokine receptor like factor 1 decrease aggrecan 
and type II 
collagen synthesis  
  [20, 26] 
Gremlin-1 BMP antagonist, 
inhibit bone 
mineralization 
↘  [14, 35] 
IGFBP-2, -3, -4, -5, -6, -7  IGFBP3↗  [12, 18, 20-22, 
24-27, 30] 
IL-6, -8, -17β  IL-17β↘ IL-6, -8↗ [14, 19-21, 25, 
27, 33] 
Inhibin-βA/proinhibin-βA dimerise to form 
Activin A, 
stimulating 
TIMP-1 
production 
↗ ↗ [12, 16, 20, 27] 
Leukocyte cell-derived 
chemotaxin 2 (LECT2) 
reduce IL-1β, IL-6 
and other 
chemokines reduce 
IL-1β, IL-6 and 
↗  [18, 33] 
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other chemokines 
[79] 
Pleiotrophin (PTN)   ↗ [14, 33] 
TGF-β2    [22] 
Enzymes Specificity   References 
ADAMTS-1, -2,  -4 ,-5    [12, 22, 25] [20] 
Angiogenin Deep layer – 
stimulate 
angiogenesis 
↗  [12, 18, 32-34, 
37] 
Carboxypeptidase E    [14] 
Cathepsins (B, D, F, K, L1, Z)  B↗  [12, 14, 16, 18, 
20-22, 25, 30, 35] 
ENPP2 NTP 
pyrophosphatase, 
mineralization 
  [22] 
Extracellular sulfatase Sulf1  Sulf2    [14] 
HTRA1 (serine protease) Increase with TGF-
β1 
 
↘  [12, 14, 16, 18, 
22, 24, 26, 30, 32, 
34, 35, 37] [20] 
Lysozyme C   ↗ [12, 14-16, 20, 
32, 34] 
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MMPs (-1, -2, -3, -7, -10, -13, -14, -
16) 
 ↗ ↗ [12-16, 18, 20-25, 
27, 30, 31, 34, 35, 
37] 
Pappalysin-1 Metalloproteinase, 
cleave IGFBP-4,-5 
  [22] 
Peroxiredoxin-1, -2, -4 protecting cells 
from free-radical 
damage  
2↗  [13, 16, 20, 23, 
37] 
Phospholipase A2*  ↗  [12, 13, 32, 34, 
35, 37] 
Procollagen C-endopeptidase 
enhancer (PCOLCE)-1, -2 
enhances 
procollagen C-
proteinase activity. 
C-terminal 
processed part of 
PCPE (CT-PCPE) 
may have an 
metalloproteinase 
inhibitory activity. 
Decrease with 
TGF-β1 
↗  [12, 14-16, 18, 
22, 24, 26, 30, 33, 
34, 37] [20] 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 1, 2  
Collagen fibre 
glycosylation 
 
 ↗ [22, 31, 58] 
Putative tryspin 6 (serine protease)    [21] 
Pyruvate kinase  ↑  [12, 13, 22]  
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Serine protease 23    [22] 
Sulfhydryl oxidase    [12, 22]  
Superoxide dismutase (SOD1, 
SOD2, SOD3) 
protecting cells 
from free-radical 
damage 
 SOD2↘ [12, 14-16, 22, 
23, 25, 31, 32, 34, 
35]  
Triosephosphate isomerase :  Carbohydrate 
degradation 
 ↗ [12, 14, 16, 20, 
22]  
Enzymatic inhibitors Specificity   References 
Antileukoproteinase   Serine proteinase 
inhibitor 
  [12, 25] 
Cystatin C Cysteine proteinase 
inhibitor 
  [18, 21, 22, 26] 
Inter α Globulin inhibitor H2  HA processing   [12] 
Inter α trypsin inhibitor  HA processing,    
           Heavy chain H1  ↗  [13] 
           Heavy chain H4    [18] 
SERPIN Serine protease 
inhibitors 
   
   A1 : α1-antitrypsin    [16, 21, 22, 25, 
32, 34] 
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   A2: anti-trypsin related protein       [22] 
   A3 : α1-antichymotrypsin  ↘  [12, 16, 18, 22, 
25, 30, 32-35]  
   A5 : Protein C inhibitor    [12, 22]  
   E1:    Plasminogen activator 
inhibitor 1 
   [18, 22, 30, 35] 
   E2 : Glia-derived nexin    [14, 20-22, 32, 
35] 
   F1: Pigment epithelium derived 
factor 
 ↗  [12, 13, 16, 18, 
30] 
   G1: Plasma protease C1 inhibitor    [18, 22, 30] 
   I2 α1 antiproteinase 2    [14, 15] 
TIMPs (-1, -2, -3, -4) TIMP-1 increase 
with TGF-β1 
 TIMP-1↘ [12, 14-16, 18, 
20-22, 24-26, 30, 
34, 35, 37] 
Tissue factor pathway inhibitor 1, 2 
(TFPI)  
Serine protease 
inhibitors 
  [26] 
Miscellaneous Specificity   References 
78kDa glucose regulated protein    [22, 33-35] 
A1 acid glycoprotein 1, 2 Binding and 
modulation of 
cytokines and 
↗  [13, 34] 
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growth factor, like 
IL-6 and TNF-α 
ADAMTS-like 2  Bind to LTBP – no 
enzymatic function 
  [25] 
Annexin A1, A2, A5,  A1, A2 ↗  [14, 18, 20, 22, 
30, 35] 
Apolipoprotein AI, AII , D, E Bind lipids – 
proteoglycans and 
collagens 
interaction 
AI, AII↗ 
D↘ 
 [13, 18, 19, 30, 
34, 35] 
CILP (1-1, 1-2, 2-1, 2-2) No intrinsic NTP 
pyrophopshatase 
activity but IGF-
1/TGF-β 
antagonists, 
increase with TGF-
β1 
↗ ↗ [12, 14, 16, 18, 
20, 24, 25, 32, 34, 
36, 37] 
Chondroadherin Bind the cell to the 
type II collagen 
  [13, 14, 16-18, 
20, 25, 32-35, 37] 
Clusterin Chaperon – inhibit 
protein aggregation 
and apoptosis 
↘  [14-20, 22, 24, 
26, 30, 34, 35, 37]  
Complement C1q, C1r, C1s, C3, C8, 
C9, factor B, factor D, factor H 
 B, C1r, C3 
↗ 
 [12-14, 16, 18, 
20-22, 30, 32, 33, 
37] 
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Emilin-1 Cell-ECM 
interaction 
  [25, 35, 37] 
Ezrin-Radexin-Moesin-Transgelin Cytoskeletal related   [13, 20, 22, 27, 
32, 35, 80] 
Gelsolin Cytoskeletal related ↗  [16, 18, 20, 22, 
26, 30-32, 34, 35, 
37, 80] 
Lactadherin    [15, 18, 20-22, 
30] 
Osteonectin (SPARC) ECM-cytokine 
interactions 
  [14-16, 18, 22, 
24, 25, 30, 33-35] 
Osteopontin Bind to mineral and 
inhibit 
mineralization 
↗  [13, 20, 34, 37] 
Profilin-1 Cytoskeletal related   [18, 20, 27, 30, 
80] 
S100A1 Calcium binding 
proteins, role in 
inflammation 
A1↘ 
A8, A10↗ 
 [13, 19, 21, 22, 
25, 27, 32-35] 
Semaphorin 3A, 3C    [22] 
Spondin -1 and -2   Cell adhesion-bind 
GAGs-Wnt agonist 
  [12] 
Stanniocalcin 1, -2    [18, 26, 30] 
31 
 
Tetranectin Mineralization – 
bind to GAGs 
↗  [13, 18, 21, 30] 
TGFBI (Transforming Growth 
Factor, Beta-Induced) 
Cell to type II 
collagen 
interactions, 
endochondral bone 
formation 
↗  [13, 14, 18, 20-
22, 27, 30, 32-35, 
80] 
Thrombospondin-1, -3, -4 Cell-ECM 
interaction - 
angiogenesis 
-3↗ -1↗ [13, 14, 17-22, 
24, 30, 32, 34, 35, 
37] 
Vasorin may act as an 
inhibitor of TGF-β 
signalling 
  [22] 
 
Table 2: Characteristics of the reviewed studies. 
Study Method Secretome Chondrocyte 
culture 
Explant 
culture 
Peffers et al 2013 [12] OA +/- IL-1β X  X 
Lourido et al 2014 
[13] 
Normal vs wound or 
unwound OA 
X  X 
Svala et al 2015 [14] Equin +/- IL-1β X  X 
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Williams et al 2013 
[15] 
Equin +/- IL-1β X  X 
Hermansson et al 2004 
[16] 
OA only X  X 
Clutterbuck et al 2011 
[17] 
Equin +/- IL-1β X  X 
Peffers et al 2016 [20] Equin +/- IL-1β X  X 
Polacek et al 2010 [18] OA monolayer vs explant 
culture 
X X X 
Swan et al 2013 [19] Canine +/-IL-1β X  X 
Calamia et al 2012 
[21] 
Normal + IL-1β X X  
Calamia et al 2014 
[22] 
OA +/- chondroitine or 
glucosamine sulfate 
X X  
Catterall et al 2006 
[23] 
OA +/- IL-1β X X  
Riffault et al 2015 [24] OA +/- TGF-β1 X X  
Stenberg et al 2013 
[25] 
Early OA vs late OA X X  
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Rocha et al 2014 [26] bMSCs chondrogenic 
differentiation 
X X  
Lourido et al 2015 
[27] 
OA or normal+IL-1β X X  
Taylor et al 2015 [28] Bovine P0 vs P2 
chondrocytes 
X X  
Haglund et al 2008 
[29] 
Rat, +/- LPS X X  
Polacek et al 2011a 
[30] 
Chondrocytes vs MSCs X X  
Polacek et al 2011b 
[31] 
Monolayer vs aggregate 
culture 
X X  
Onnerfjord et al 2012 
[32] 
Type of cartilage   X 
Ikeda et al 2013 [33] Normal vs OA hip   X 
Muller et al 2014 [34] Normal at superficial vs 
intermediate vs deep layer 
  X 
Tsolis et al 2015 [35] Normal vs OA  X  
34 
 
Cillero-Pastor et al 
2013 [36] 
Normal vs OA from 
superficial to deep layer with 
MALDI-IMS 
  X 
Gago-Fuentes et al 
2015 [80] 
Cx43 complexes from 
normal vs OA chondrocytes 
 X  
Hsueh et al 2015 [37] Decellularized cartilage 
from normal vs OA, knee vs 
hip and superficial vs 
intermediate vs deep layer 
  X 
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